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Placement of a retrievable inferior vena cava filter
for deep venous thrombosis in term pregnancy
Yang Liu, MM, Yan Sun, MM, Shiyi Zhang, MM, and Xing Jin, MD, Ji’nan, China
Objective: Venous thromboembolism is a significant cause of morbidity and death in pregnant women. Retrievable vena
cava filters were placed right before labor as prophylaxis for peripartum pulmonary embolism.We reviewed the experience
of caval filter placement and retrieval in term pregnancy in this study.
Methods: We reviewed 15 patients with deep venous thrombosis (DVT) of the lower extremity who underwent OptEase
(Cordis Corp, New Brunswick, NJ) retrievable vena cava filter placement. DVT was diagnosed by clinical symptoms and
Doppler ultrasound imaging. Subcutaneous low-molecular-weight heparin was eased 12 hours before cesarean delivery
and restarted 12 hours after delivery. The caval filters were placed suprarenally from the jugular approach and retrieved
from the femoral approach.
Results: The filters were successfully placed in all patients on the day of cesarean delivery. No placement-related
complications occurred. The caval filter was left in situ as a permanent device in one patient because the captured
thrombus within the filter was not eliminated after the thrombolytic therapy. Filters in other 14 patients were retrieved
successfully, without difficulty, including in one patient after complete lysis of captured thrombus by the thrombolytic
therapy. Oral warfarin therapy was recommended for at least 3 months after hospital discharge, and for at least 6 months
in the patient with a caval filter left in situ. All patients were examined by Doppler ultrasound imaging during the
follow-up. None presented with symptomatic pulmonary embolism or filter-related complications.
Conclusions:OptEase retrievable vena cava filter placement and retrieval in term pregnant patients with extensive DVT of
the lower extremities is safe, effective, and feasible. The results in our study may justify prophylactic filter placement use
right before labor. (J Vasc Surg 2012;55:1042-7.)
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dDeep venous thrombosis (DVT) is a serious complica-
tion of pregnancy and delivery.1-3 Subsequent pulmonary
embolism may develop from DVT, particularly during la-
bor or just after delivery. The overall incidence of DVT and
pulmonary embolism in pregnancy is 0.36% and 0.05%,
respectively.4 Several studies1-4 have identified venous
thromboembolic diseases, including DVT and pulmonary
embolism, as the most common cause of direct maternal
death.
To reduce maternal death in pregnancy due to DVT
and pulmonary embolism, anticoagulation treatment
should be started as soon as a diagnosis is made. Warfarin is
contraindicated for use in the treatment of DVT in preg-
nancy due to its side effects. It crosses the placenta and may
cause fetal complications, among them fetal hemorrhage,
death, and neurologic malformations.5
Anticoagulation with heparin is recommended as the
standard treatment and prophylaxis against DVT and pul-
monary embolism. However, the long-term use of heparin
has been verified to be associated with bleeding, thrombo-
cytopenia, alopecia, osteoporosis, and neurologic compli-
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1042ations, among others.2,6 In recent years, low-molecular-
eight heparin (LMWH) has become an attractive
lternative to unfractionated heparin because of its low
omplication incidence.7
Although use of inferior vena cava filters in the treat-
ent of DVT in pregnancy follows no uniform protocols,
lter placement as prophylaxis of pulmonary embolism in
onpregnant patients for a short interval has been justified
n several publications.8-11 Placement of an inferior vena
ava filter is a feasible and effective choice when recurrent
hromboembolism occurs despite adequate anticoagula-
ion or when anticoagulation is contraindicated for thera-
eutic or prophylactic indications. However, the incidence
f complications associated with permanent filters has been
eported to increase with long-term use, especially in young
atients.9,12,13 Thus, retrievable caval filters become an
ttractive option for this situation. OptEase retrievable vena
ava filters (Cordis Corp, New Brunswick, NJ) were placed
n our patients, who were considered to be at high risk of
ntrapartum and postpartum pulmonary embolism. This
tudy reviews our experiences of caval filter placement right
efore labor in term pregnant women with extensive DVT
f the lower extremities. The efficacy, safety, complications,
nd follow-up outcome associated with caval filter place-
ent in term pregnancy are presented in this study.
ETHODS
Between August 2006 and October 2010, 15 patients
ith DVT of the lower extremities in term pregnancy were
ndicated for retrievable vena caval filter placement in our
epartment (Table). These 15 patients were a mean age of
9.4 years (range, 20-41 years). None of them had a history
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Volume 55, Number 4 Liu et al 1043of DVT before pregnancy, and the initial symptoms pre-
sented in the third trimester (range, 34-40 weeks). Swelling
occurred in the left leg in 13 patients and in the right leg in
two. No patient had symptoms of pulmonary embolism.
Coagulation parameters, including protein C, protein
S, antithrombin III, lupus anticoagulant antibodies, and
anticardiolipin antibodies, were examined in all patients
before the delivery, but no abnormalities were found.
Doppler ultrasound imaging demonstrated DVT location
at the outset, including iliofemoropopliteal thrombi in nine
patients, femoropopliteal thrombi in five, and gastrocne-
mius thrombus in one.
All patients were subcutaneously injected with 4100 IU
anti-Xa of LMWH every 12 hours and were also treated
with bed rest and leg elevation until the acute swelling was
resolved. All patients were fitted with compression stock-
ings during ambulation. The injection was ceased 12 hours
before cesarean delivery began and restarted 12 hours after
delivery. The cesarean delivery was performed in all women
to minimize the risk of subsequent pulmonary embolism.
The inferior vena cava filter placement was performed as
prophylaxis of intrapartum and postpartum pulmonary em-
bolism due to short-term discontinuance of anticoagula-
tion treatment during labor and also rapid decompression
of the venous system after delivery.
All patients gave informed consent before the proce-
dure. The filter was inserted on the day of cesarean delivery,
under local anesthesia through the right internal jugular
vein. Cavography was performed through a pigtail catheter
to identify the level of the renal vein by means of fluoros-
copy guidance (Fig 1, A). The OptEase caval filter was
inserted into the inferior vena cava and deployed suprare-
nally with the aid of a pusher. The position of the deployed
filter was checked with cavography (Fig 1, B). The fetus was
shielded as much as possible with a lead shield during the
Table. Demographics and outcomes of pregnant patients
Pt
Age
(years) G/P
DVT onset
(weeks) Laterality
DVT locatio
at the outse
1 26 G1P0 37 Left IVFVPV
2 29 G1P1 37 Left IVFVPV
3 20 G1P0 36 Left FVPV
4 31 G1P0 39 Left IVFVPV
5 28 G1P0 38 Right VFVPV
6 27 G1P0 36 Left FVPV
7 33 G1P1 40 Left IVFVPV
8 31 G1P0 37 Left IVFVPV
9 25 G1P0 36 Left FVPV
10 28 G1P0 37 Right IVFVPV
11 41 G1P1 34 Left GV
12 35 G1P1 38 Left IVFVPV
13 26 G1P0 37 Left IVFVPV
14 32 G1P0 39 Left FVPV
15 29 G1P0 37 Left FVPV
FV, Femoral vein; G, gravida; GV, gastrocnemius vein; IV, iliac vein; P, para
aThe filter was retrieved after thrombolytic therapy for trapped thrombus.
bThe filter was left in situ.procedure. wThe retrieval of caval filter was scheduled 12 to 14 days
fter placement. An ultrasound examination was performed
efore retrieval to confirm whether there were large cap-
ured thrombi within the filter. Cavography was performed
hrough the femoral vein to exclude filter migration and
rapped thrombi again. A 10F catheter containing the
etrieval loop system was inserted into the infrarenal infe-
ior vena cava, 2 to 3 cm below the filter hook. The hook at
he lower end of the filter was grasped by the loop (Fig 2,
). The catheter advanced until the filter collapsed and was
ollected in the catheter and removed (Fig 2, B). Postre-
rieval cavography was performed and manual hemostasis
deep vein thrombosis (DVT)
Gestational age
at delivery
(weeks)
Duration of
caval filter
(days)
Follow-up
duration
(months)
Ultrasound after
discharge
(months)
39 13 12 3
39 15a 12 3
38 12 12 3
40 14 48 3, 6, 12
39 12 12 3
38 14 12 3
41 14 28 3, 6, 12
39 14 12 3
39 9 12 3
38 12 12 3
37 b 18 3, 6, 12
39 14 12 3
39 12 12 3
41 14 9 3
40 13 6 3
popliteal vein.
ig 1. A, Cavography before the filter deployment. B, Cavogra-
hy shows the deployed filter.with
n
t
; PV,as achieved. If large thrombi that could result in symp-
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April 20121044 Liu et altomatic pulmonary embolism were trapped in the filter, we
initiated short-term thrombolytic therapy with urokinase
before the filter was removed. The filter would be left in situ
as a permanent device if the trapped thrombus were not
dissolved.
RESULTS
OptEase retrievable caval filter placement was success-
fully performed in 15 patients just before cesarean delivery.
No placement-related complications were observed. The
retrievable caval filters were inserted through the right
internal jugular vein and deployed suprarenally in all pa-
tients. The diameter of the inferior vena cava was30mm, so
the filters were successfully deployed without any difficulty.
Cavography just after placement did not show the presence of
advanced tilt (30°) or any cava injury. The mean fluoro-
scopic time during filter placement was usually2 minutes.
The retrievable filters were left in place for a mean of 13
days (range, 9-15 days), excluding the woman with a caval
filter left in situ. No perioperative maternal or fetal compli-
cations occurred. Apgar scores were within normal ranges
in all babies. No complications, such as pulmonary embo-
lism, hemorrhage, infection, or filter migration or fracture,
were observed.
Before the retrieval, ultrasound imaging demonstrated
large thrombi had been captured by the filters in two
patients, which were considered to have arisen from DVT
in the lower extremity. Thrombolytic therapy was com-
menced in these two patients by systemic administration of
400,000 IU/d urokinase for 4 days. Cavography revealed
the captured thrombus was completely dissolved in one
patient but was not eliminated in the other woman (Fig 3).
Fig 2. A, The hook at the lower end of the filter was grasped by
the loop. B, The collected filter has been withdrawn into the
catheter.The retrieval was abandoned finally and the filter was left in iitu as a permanent device. Filters in the other 14 patients
ere retrieved successfully without any procedure-related
omplications. The mean fluoroscopy time during retrieval
as 7.8 minutes (range, 5.3-14.7 minutes), comparable to
eported times in the literature. Cavography after retrieval
evealed no extravasation, inferior vena cava stenosis, or
ein wall injury in the 14 women.
Oral warfarin therapy was recommended to maintain a
artial thromboplastin-international normalized ratio of
.0 to 3.0 for at least 3 months after discharge and for at
east 6 months in the patient with a caval filter left in situ.
linical follow-up was available for these 15 patients for a
ean of 15months (range, 6-48months). All patients were
xamined by means of venous duplex ultrasound imaging
efore the discontinuance of oral warfarin therapy during
he follow-up.
No symptomatic pulmonary embolism or filter-related
omplications occurred. Twelve patients were completely
symptomatic, but patients 4, 7, and 11 (Table), including
he woman with a caval filter left in situ, presented with
ignificant unilateral leg swelling caused by partial resolu-
ion of DVT, as documented by Doppler ultrasound imag-
ng 3 months after discharge. However, abdominal ultra-
ound imaging revealed no filter fracture, migration, total
aval occlusion, or new thrombus in the filter. Routine tests
f urine and kidney function were normal in this woman.
hese three patients were treated with long-term oral war-
arin anticoagulation (6 months) and compression stock-
ngs (12 months) until the leg swelling recovered. They
ere also followed up by further ultrasound imaging.
ISCUSSION
The risk of DVT and subsequent pulmonary embolism
ig 3. The trapped thrombus (arrow) was not dissolved after
hrombolytic therapy.n pregnant women is six times higher than in nonpregnant
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Volume 55, Number 4 Liu et al 1045women due to the hemodynamic changes and the changes
in the coagulation and fibrinolytic systems during preg-
nancy.10 Thromboembolic disease was reported to be the
most common cause of maternal deaths during the perina-
tal period.1-3 During the first 3 postpartum months vs
pregnancy, the relative risk (RR) for venous thromboem-
bolism was determined to be more than five times higher
(5.33; 95% confidence interval [CI], 3.55-8.02; P  .001)
and the relative risk for DVT alone was more than four
times higher (P.001); pulmonary embolism occurs more
commonly during the postpartum period than during preg-
nancy (RR, 15.0; 95% CI, 5.1-43.9).14 Gherman et al15
reported 127 cases of venous thromboembolism and 38
patients with pulmonary embolisms, of which 23 (60.5%)
occurred in the postpartum period. Postpartum thrombosis
was also said to be three to five times as frequent as
antepartum events by Aaro and Juergens16 and Kierkeg-
aard.17 Rutherford et al18 thought the immediate postpar-
tum period after delivery was the period of greatest risk for
pulmonary embolism. The postpartum period is conceded
to be the highest-risk period for venous thromboembolism
and pulmonary embolism in pregnant patients.
To reduce morbidity and maternal death in pregnancy,
anticoagulation treatment with heparin needs to be com-
menced immediately once DVT is diagnosed. We always
administer full-dose LMWH for patients who develop
DVT during pregnancy. However, it results in the in-
creased risk of peripartum hemorrhage during vaginal or
cesarean delivery and is therefore ceased 12 hours before
labor.19 Paradoxically, the risk of pulmonary embolism
increases due to the discontinuance of anticoagulation and
the hemodynamic changes accompanying the rapid decom-
pression of the venous system after delivery.20,21 So we
think patients with DVT in term pregnancy are at particu-
larly high risk of intrapartum and postpartum pulmonary
embolism, which is why we have preferred to take active
intervention therapy in this situation during the past 5
years.
Other treatment options include thrombectomy,
thrombolytic agents, such as urokinase, and inferior vena
cava filter placement.22 Thrombectomy can remove the
source of emboli but results in considerable blood loss and
is reserved for patients with venous gangrene due to exces-
sive limb swelling. Urokinase may precipitate labor and
produce an atonic uterus because of the interference of
fibrin degradation products with uterine contraction and is
therefore confined to treat life-threatening pulmonary em-
bolism.
Inferior vena cava filter placement was first reported by
Greenfield in 1967. The procedure has been justified to
reduce the risk of significant recurrent pulmonary embo-
lism to 1% to 3% in the nonpregnant population.23 Caval
filter placement in pregnancy was first presented in 1973.
However, use of an inferior vena cava filter during preg-
nancy has been rarely described in the large number of
patients. AbuRahma and Mullins24 reported their experi-
ence in Greenfield (Boston Scientific, Natick, Mass) filter
placement in 18 pregnant women with extensive iliofemo- eal DVT immediately before labor. Kawamata et al25 pub-
ished their experience of temporary caval filters placed to
revent pulmonary embolism in pregnant women with
VT. These two reports justified the safety, efficacy, and
easibility of two different types of vena cava filter during
regnancy and also presented different complications and
ollow-up results. However, the indications, selection of
urgery time, and duration of filters were not exactly the
ame.
The indications of caval filter placement in nonpreg-
ant patients is definite.10-13,26 It is recommended in pa-
ients with confirmed DVT or pulmonary embolism with a
ontraindication to or complication with heparin therapy
r recurrent pulmonary embolism despite adequate antico-
gulation. Other relative indications include a free-floating
hrombus documented by means of Doppler ultrasound
maging and the presence of extensive iliac thrombosis that
ay result in pulmonary embolism. Indications for inferior
ena cava filter placement in patients with DVT early in the
rst or second trimester of pregnancy are in accord with
hose in nonpregnant patients.24,25 In our series, caval filter
lacement was conducted for prophylactic prevention of
ntrapartum and postpartum pulmonary embolism in term
regnant patients with DVT of the lower extremities. This
rocedure was performed in 15 patients just before labor
nd anticoagulation therapy was discontinued.
The mode of delivery was not affected by the caval filter
nd was based on obstetric indications in all cases.27 Some
uthors,10 however, chose cesarean section tominimize the
isk of release of thrombi and subsequent pulmonary em-
olism. Gherman et al15 concluded that there was no
ncreased incidence with surgical procedure among 127
ases of DVT and 38 cases of pulmonary embolism during
regnancy. However, they reported that postpartum DVT
hat occurred after spontaneous vaginal delivery did occur
arlier than those associated with cesarean delivery (2.3 
.7 vs 6.3  1.1 days, P  .004).
The cesarean section performed in our patients was also
uided by the following considerations: First, duration of
esarean section was usually 40 minutes, and LMWH
njection was restarted 12 hours after delivery. Compared
ith vaginal delivery, duration of discontinuance of antico-
gulation was much shorter; therefore, the risk of postpar-
um DVT and pulmonary embolism was decreased.
Second, the swelling of lower extremities was usually
ot relieved completely before labor. Our colleagues in the
bstetrical department considered that the swollen lower
xtremities would interfere with the vaginal delivery be-
ause the women would need the help of both legs.
Third, the patients could start ambulation early after
esarean section delivery, which was the same as patients
fter vaginal delivery. In conclusion, the cesarean section
elivery was planned to provide good control over the
iming of our patients’ anticoagulation.
The placement of a permanent filter in young women
hould be contentious, especially in patients who have long
ife expectancies and only a transient risk of pulmonary
mbolism.26 Venous injury or perforation, the recurrence
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placement of the filter, and renal dysfunction associated
with a suprarenal permanent filter are possible complica-
tions.9,11,12,28 We therefore recommend permanent caval
filter placement as adjunctive therapy for patients in early
pregnancy with extensive thrombus or recurrent emboli
despite anticoagulation.
In recent years, retrievable inferior vena cava filters have
been accepted for a short indwell time to prevent intrapar-
tum pulmonary embolism.10,11,24,25 However, the use of
retrievable filters in obstetrics is limited to case reports only,
and no severe adverse events have been reported. In our
patients, we preferred to use the OptEase caval filter be-
cause of its good retrievability and improved clot trapping
ability. The OptEase vena caval filter has a symmetric
double basket design and anchoring barbs on the superior
end of each of the six straight struts.11 A hook at the inferior
end of the basket enables a smooth retrieval. The filter can
be inserted percutaneously by the internal jugular vein or
the femoral vein through a 6F introducer sheath and be
retrieved through the femoral vein using a 10F retrieval
system.
On the basis of experience, OptEase caval filters should
be removed 14 days after delivery to avoid endotheliali-
zation and incorporation of the caval wall into the filter.
The increased dwell time increases the failure of filter
retrieval because of the incorporation into the caval
wall.11,24 But whether caval filters are more likely to un-
dergo rapid endothelialization is still unknown. When the
filters were retrieved, we sometimes found fresh thrombi
adhering to the filters. In our opinion, these thrombi had
formed because of the filters themselves but were too small
to cause symptomatic pulmonary embolism.
In addition, if a trapped thrombus is not dissolved after
the thrombolytic therapy, the filter could be left in situ as a
permanent device. In fact, it is difficult to differentiate from
imaging features a true thrombosis (native formation of
thrombus) within an inferior vena cava filter from capture
of thrombus in the filter from a distal source.29 Such a
differentiation can only be made with certainty with histo-
pathologic analysis. However, Tardy et al29 have suggested
that early (6 months) IVC filter thrombosis is likely to be
secondary to DVT in the lower extremity.
The retrievable vena caval filters were deployed above
the level of the renal veins in our series. The selection of
deployment position is guided by the following consider-
ation. Pregnancy is one of the few indications for suprarenal
placement of the filter to avoid the contact between the
gravid uterus and the filter.30 The filter in this site will not
be displaced by the contracting uterus during delivery and
will provide protection against thrombus developed from
ovarian veins. Infrarenal placement of caval filters may
induce caval thrombosis or injury of the vessel wall or
uterus and possible filter migration.30,31 The suprarenal
filter may increase risk of renal dysfunction. As seen in our
study, however, no severe complications associated with
the caval filter in situ were observed during the follow-up. lIn our study the caval filter was placed through the
ight internal jugular vein. Placement through this access is
imple, well tolerated by the patients, and decreases the risk
f iatrogenic embolization resulting from manipulations at
he pelvic veins in patients with extensive iliofemoral
hrombosis. Among the complications associated with jug-
lar access are air embolism, heart arrhythmias, and hemo-
ericardium, which several publications have described.31
he ovarian access was recommended by several authorities
ut was not accepted widely because thrombus might fall
ff and cause pulmonary embolism during the proce-
ure.24,32,33 The safety and feasibility of caval filter place-
ent through ovarian access were still not satisfactory.
Another concern about the filter placement is the risk of
xposing the fetus to radiation. In fact, the necessary fluo-
oscopy for the procedure required 2 minutes for each
oman. It has been estimated that 2 minutes of fluoros-
opy to the abdomen is within the safety limit of fetal
xposure.34 The use of ultrasound imaging as a means of
iagnosis of DVT in pregnancy is also recommended to
inimize the exposure of fetus to radiation. Besides, it was
alculated that the radiation was0.05 rad with abdominal
hielding.35 With careful use of the available procedure, the
isk of exposure during the caval filter placement was small
n relative and absolute terms.
Several recent studies reported intravascular ultrasound
nd external Doppler ultrasound scanning were both suc-
essfully used in vena caval filter placement.36,37 It was used
n patients in whom being transported to the operating
oom or radiology department presented a risk, such as
hose in the intensive care unit.
Visualization is the only limiting condition to place-
ent, especially in overweight patients and pregnant
omen.38 These techniques will eliminate the need for
uoroscopy during pregnancy, thereby avoiding fetal expo-
ure to radiation. However, evidence that justifies the safety
nd feasibility of this technique in pregnant women over
he long term is still absent.
Although venous thromboembolism is a serious com-
lication of pregnancy and delivery, the overall incidence of
VT and pulmonary embolism in pregnancy is still low
ith adequate preventive measures. Moreover, the symp-
oms of some patients with DVT and pulmonary embolism
re masked by the discomforts of term pregnancy. So, our
tudy is limited by its small size and the lack of a control
roup, limitations that have been also encountered in most
eries on pregnant patients with DVT. However, in some
ay, our research could justify the safety, efficacy, and
easibility of inferior vena cava filter placement in term
regnant patients with DVT who are about to deliver. We
elieve that careful patient selection and experienced endo-
ascular surgeons will continue to expand the applicability
f this procedure in complicated situations.
ONCLUSIONS
OptEase retrievable vena cava filter placement and re-
rieval in term pregnant patients with extensive DVT of the
ower extremities is safe, effective, and feasible. Its prophy-
11
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
JOURNAL OF VASCULAR SURGERY
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However, the long-term safety and efficacy of retrievable
caval filters in term pregnant women are still unknown and
require further research.
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